Sign up for our special edition newsletter to get a daily update on the coronavirus pandemic.

Pfizer’s COVID-19 vaccine is likely to protect against the highly contagious mutant strain that has spread across the UK, a new study revealed.

Researchers involved in the study — which was posted online Tuesday but has yet to be published or peer-reviewed — engineered pseudoviruses with the full set of mutations present in B117, the coronavirus variant detected in Britain.

They then tested blood from 16 people who had received the vaccine, and determined that the vaccine was able to neutralize the variant just as well as the earlier strain of the virus.

The researchers determined that “these data … make it unlikely that the B.1.1.7 lineage will escape” the protection of the vaccine.

Pfizer revealed last week that a similar laboratory study indicated the vaccine was effective against a key mutation, called N501Y, found in both the UK and South Africa variants, Metro UK reported.

The new study results are based on a more extensive analysis.

Late last month, Dr. Ugur Sahin, BioNTech’s co-founder and CEO who co-founded the vaccine, said he is “confident” it will be effective against the UK strain.

However, he warned that the variant may make it harder for countries to achieve “herd immunity” against COVID-19, which is believed to involve inoculating 60 to 70 percent of a population against the disease, according to the Wall Street Journal.

And Moderna also expressed confidence in its vaccine’s ability to protect against the new strain, stating that research has shown the jab is “equally effective” against several other variants of the virus that emerged earlier in the pandemic.